Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q4 2022 Earnings Presentation
14 slides from Phibro Animal Health's earnings presentation, Aug 25, 2022
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call August 25, 2022 Financial Results U.S. toll-free +1-833-968-1955 Fourth Quarter and Year Ended June 30, 2022 International toll +1-647-689-6656 Conference ID: 3927884
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and leverage levels. All statements other than statements of historical or current
Slide 3: Key Themes
Key Themes Fourth Quarter Our industry faces Phibro Further growth Exciting addition to Strong demand for our macro-economic and continues projected in our Companion Animal product portfolio operational challenges to act FY 2023 development pipeline Year-over-year net sales Although countries are Pr
Slide 4: Companion Animal Development Pipeline
Companion Animal Development Pipeline * Estimated Addressable Market amounts are management’s estimate as of the date hereof derived from publicly available information, our industry knowledge and assumptions based on such information and knowledge. We believe these estimates are reasonable, however
Slide 5: Financial Performance - Consolidated (Fourth Quarter)
Financial Performance - Consolidated Fourth Quarter, Year-on-Year comparison $ in millions, except per share data Net Sales – an increase of $35.0 million, or 16%, driven by YOY growth in all three business segments: Animal Health, Q4 %∆ Mineral Nutrition and Performance Products Net Income & Di
Slide 6: Financial Performance - Consolidated (FY 2022)
Financial Performance - Consolidated FY 2022, Year-on-Year comparison $ in millions, except per share data Net Sales – an increase of $108.9 million, or 13%, driven YOY again by growth across all three business segments: FY 2022 %∆ Animal Health, Mineral Nutrition and Performance Products Consolid
Slide 7: Financial Performance – Animal Health (Fourth Quarter)
Financial Performance – Animal Health Fourth Quarter, Year-on-Year comparison $ in millions Net Sales – an increase of $19.8 million, or 13% YOY MFAs and other – an increase of $10.5 million, or 12% Q4 %∆ Higher average selling prices and increased sales of processing aids used in the ethanol
Slide 8: Financial Performance – Animal Health (FY 2022)
Financial Performance – Animal Health FY 2022, Year-on-Year comparison $ in millions Net Sales – an increase of $61.3 million, or 11% YOY MFAs and other – an increase of $31.5 million, or 10% FY 2022 %∆ Increased demand for MFAs, particularly in the Latin America and Canada region, coupled wit
Slide 9: Financial Performance – Other Segments (Fourth Quarter)
Financial Performance – Other Segments Fourth Quarter, Year-on-Year comparison $ in millions YOY Q4 %∆ Mineral Nutrition Mineral Nutrition Net Sales $ 69.4 22% Net Sales increased $12.6 million, or 22%, primarily driven by higher average selling prices of trace minerals Adj. EBITDA $ 6.7 44% A
Slide 10: Financial Performance – Other Segments (FY 2022)
Financial Performance – Other Segments FY 2022, Year-on-Year comparison $ in millions YOY FY 2022 %∆ Mineral Nutrition Mineral Nutrition Net Sales increased $39.0 million, or 18%, driven by higher average Net Sales $ 259.5 18% selling prices of trace minerals Adj. EBITDA $ 24.0 40% Adjusted EB
Slide 11: Key Capitalization Metrics
Key Capitalization Metrics FY 2022 Highlights ($5) million of trailing 12-month free cash flow; operating Free Cash Flow cash flow of $32 million less capital expenditures of $37 million 3.9x gross leverage ratio; $434 million total debt / Leverage $111 million trailing 12-month Adjusted EBITDA $194
Slide 12: Financial Guidance Fiscal Year 2023
Financial Guidance Fiscal Year 2023 $ in millions, except earnings per share (EPS) data Although macroeconomic headwinds are anticipated to FY 2023 persist, we are projecting consolidated Net Sales growth of Actual Full Year Guidance 2% to 6% FY22 Low High Low High Animal Health, 3% to 7%: Conso
Slide 13: Q&A
Phibro 13 August 25, 2022 HEALTHY ANIMALS, HEALTHY FOOD. HEALTHY WORLD. ANIMAL ALF CORPORATION 0
Slide 14: © 2022 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy
© 2022 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy Animals. Healthy Food. Healthy World.; and any other Phibro brand or brands shown herein are trademarks owned by or licensed to Phibro Animal Health Corporation or its affiliates. Any other trademark that